Our top pick for
Entrada Therapeutics Inc is a biotechnology business based in the US. Entrada Therapeutics shares (TRDA) are listed on the NASDAQ and all prices are listed in US Dollars. Entrada Therapeutics employs 114 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$12.18|
|52-week range||$5.12 - $36.85|
|50-day moving average||$7.11|
|200-day moving average||$13.12|
|Wall St. target price||$10.00|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-4.68|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-06-24)||24.16%|
|1 month (2022-06-01)||112.57%|
|3 months (2022-04-01)||31.96%|
|6 months (2021-12-31)||-28.86%|
|1 year (2021-06-27)||N/A|
|2 years (2020-06-27)||N/A|
|3 years (2019-06-27)||N/A|
|5 years (2017-06-27)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-18.29%|
|Return on equity TTM||-40.59%|
|Market capitalisation||$307.7 million|
TTM: trailing 12 months
We're not expecting Entrada Therapeutics to pay a dividend over the next 12 months.
Entrada Therapeutics, Inc. , a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1. It also engages in the development of EEV-PMO-CAG for the treatment of myotonic dystrophy type 1. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.